Navigation Links
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Date:1/8/2014

MOUNTAIN VIEW, Calif., Jan. 8, 2014 /PRNewswire/ -- The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.

New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Despite the popularity of VEGF inhibitors in the U.S., issues of patient preference and compliance, the risk of infection, as well as side effects such as floaters, increased intraocular pressure and inflammation of the eye exist," said Frost & Sullivan Life Sciences Senior Industry Analyst Debbie Toscano. "There is also a lack of substantive long term data on the ability of VEGF therapy to prevent visual impairment."

In addition, the rapid uptake of low-cost Avastin, supplied by compounding pharmacies, is challenging the VEGF inhibitors market. Although the U.S. Food and Drug Administration has drawn attention to safe
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Cleared for Quotation on OTCQB
2. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
3. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
4. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
7. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
8. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
9. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
10. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
11. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 With ... cytometry is experiencing a rise in active partnerships. ... in underdeveloped nations to quantitate CD4 cell markers ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... the Global Flow Cytometry Market ( http://www.frost.com/nf0e ), ...
(Date:8/31/2015)...  The departments of Drug and Alcohol Programs (DDAP) ... 90 to raise awareness for International Overdose Awareness Day ... Pennsylvania and help more Pennsylvanians with substance ... the Building Bridges to Recovery initiative. ... to a disease that is fully treatable, if given ...
(Date:8/31/2015)... Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest independent ... & CEO, and Sean Whelan , CFO, will present ... and Mr. Whelan are scheduled to participate in the Wells ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... participate in the Robert W. Baird 2015 Healthcare Conference in ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... interviewed dating men and pick-up artists about their experiences of female beauty, women’s ... bodily concerns, including penis issues, as well as their relationships with other men, ...
(Date:9/1/2015)... ... ... every family has them. Whether it’s a morning routine, meal time routine or weekly ... Here are three reasons why routines can be beneficial for a child: , 1. ... implemented into a child’s schedule, they are able to anticipate what will happen next ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, ... safety labels and stickers to keep little ones' safety top of mind at all ... has a particular focus. According to the JPMA's Baby Safety Zone website, this year's ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly Hair Solutions™ is ... This highly anticipated partnership between Curly Hair Solutions™ and Trade Secrets allows for ... Torch and the Curly Hair Solutions™ team could not be more delighted to ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... to eliminate chronic back pain – once required a long, arduous recovery. However, ... hospital stay, less pain, less blood loss and minimal muscle damage. These advantages ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4
... India have criticized the recent announcement of health ... ,Mr.Vinay Agarwal, Secretary of Indian medical Association // that ... of adding ayurveda, unani and homoeopathy subjects in the ... anybody,", ,He added: "The move would also lead ...
... stress can affect younger men with clogged arteries leading to ... in the current issue of Psychosomatic Medicine. However, women in ... tendencies, said the study., ,The researchers from University of ... of the carotid arteries, which supply blood to the head, ...
... The field of genetics has been undergoing a revolution ... common disorders and a huge amount of resources allocated ... ,This has not only added motivation to scientists working ... replace the existing knowledge with those acquired new. One ...
... bred a new kind of rat that will help them ... postmenopausal women that can lead to hypertension and heart failure., ... have created a better research rat by changing a single ... them to study salt-sensitivity in hypertension as well as explore ...
... way is a judgement to popularise smoking but a simple stating ... National Institutes of Health and the Centre for Disease Control, // ... fresh cause of concern for anti-smoking lobbies and doctors. As smoking ... says that people who smoke are less likely to visit the ...
... by new virus-induced diseases like bird flu and Japanese ... specialization in virology. The NIV and the Institute of ... would confer the degree jointly., ,"There is a ... outbreak. The course is intended to provide qualified virologists ...
Cached Medicine News:Health News:Launch Of India’s First Virology Course At Pun 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: